Sugi Predict

Sugi Predict / Compounds / SCHEMBL5966601

SCHEMBL5966601

SCHEMBL5966601

CC(C)(C)OC(=O)N[C@H](CC(=O)O)Cc1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 4/20 0.56
▸ ATM Q13315 1/20 0.55
▸ PPARG P37231 1/20 0.51
▸ PPARA Q07869 1/20 0.51
▸ MMEL1 Q495T6 3/20 0.47
▸ GAA P10253 1/20 0.47
▸ CACNA1B Q00975 1/20 0.47
▸ APP P05067 3/20 0.46
▸ CTSS P25774 6/20 0.46
▸ CTSK P43235 5/20 0.46
▸ FFAR2 O15552 1/20 0.45
▸ ACE P12821 1/20 0.45
▸ CTSL P07711 1/20 0.44
▸ CTSB P07858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL740780 1.00 MME (0.56) MMEATMPPARGPPARAMMEL1
SCHEMBL740779 1.00 MME (0.56) MMEATMPPARGPPARAMMEL1
SCHEMBL28556360 0.88 ATM (0.51) MMEATMPPARGPPARAGAA
SCHEMBL20415719 0.88 ATM (0.51) MMEATMPPARGPPARAGAA
SCHEMBL18262540 0.88 ATM (0.49) MMEATMPPARGPPARAMMEL1
SCHEMBL18262538 0.88 ATM (0.49) MMEATMPPARGPPARAMMEL1
SCHEMBL29163523 0.88 ATM (0.56) MMEATMPPARGPPARAAPP
SCHEMBL28132845 0.88 ATM (0.60) MMEATMAPPCTSSCTSK
SCHEMBL7897952 0.88 ATM (0.56) ATMPPARGPPARAAPPCTSS
SCHEMBL1519889 0.88 ATM (0.56) MMEATMPPARGPPARAAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605451-B2 Targeted plasma protein degradation NOVARTIS AG (CH) 2026-04-21 — — US disclosed
CN-117486762-A Novel compound and use method and application thereof 中国医学科学院医药生物技术研究所 2024-02-02 — — CN disclosed
US-20230398224-A1 TARGETED PLASMA PROTEIN DEGRADATION NOVARTIS AG (CH) 2023-12-14 — — US disclosed
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-09-07 — — US disclosed
US-20230089867-A1 CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER NOVARTIS AG (CH) 2023-03-23 — — US disclosed
EP-4100064-A1 TARGETED PLASMA PROTEIN DEGRADATION Novartis AG (CH) 2022-12-14 — — EP disclosed
EP-3999500-A1 SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS OncoArendi Therapeutics S.A. (PL) 2022-05-25 — — EP disclosed
CN-114174280-A Substituted aminotriazoles useful as chitinase inhibitors 昂科艾伦迪治疗法公司 2022-03-11 — — CN disclosed
EP-3887363-A1 CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER Novartis AG (CH) 2021-10-06 — — EP disclosed
WO-2021156792-A1 TARGETED PLASMA PROTEIN DEGRADATION NOVARTIS AG (CH) 2021-08-12 — — WO disclosed
US-7897619-B2 Heterocyclic modulators of PKB AMGEN INC. (US) 2011-03-01 — — US disclosed
US-7897619-B2 Heterocyclic modulators of PKB AMGEN INC. (US) 2011-03-01 — — US disclosed
US-20090275592-A1 Heterocyclic modulators of PKB AMGEN INC. (US) 2009-11-05 — — US disclosed
US-20090275592-A1 Heterocyclic modulators of PKB AMGEN INC. (US) 2009-11-05 — — US disclosed
WO-2009011880-A2 HETEROCYCLIC MODULATORS OF PKB AMGEN INC. (US) 2009-01-22 — — WO disclosed
US-20060128613-A1 Melanocortin receptor ligands THE PROCTER & GAMBLE COMPANY 2006-06-15 — — US disclosed
CN-1571796-A Melanocortin receptor ligands PROCTER & GAMBLE (US) 2005-01-26 — — CN disclosed
US-20040186151-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-23 — — US disclosed
EP-1409540-A2 MELANOCORTIN RECEPTOR LIGANDS THE PROCTER & GAMBLE COMPANY (US) 2004-04-21 — — EP disclosed
WO-2002026774-A2 MELANOCORTIN RECEPTOR LIGANDS THE PROCTER & GAMBLE COMPANY (US) 2002-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128613-A1 Melanocortin receptor ligands MC3R, MC4R, MC1R MME 988/4885ATM 4626/4885PPARG 305/4885
US-20090275592-A1 Heterocyclic modulators of PKB MTOR, PDK1, EIF4EBP1 MME 4797/4885ATM 758/4885PPARG 549/4885
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS CHI3L1, CHI3L2, CHIA MME 392/4885ATM 2618/4885PPARG 4776/4885
US-12605451-B2 Targeted plasma protein degradation M6PR, ASGR1, IGF2R MME 215/4885ATM 2817/4885PPARG 4131/4885
US-20230089867-A1 CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER PCSK9, PCSK7, PCSK6 MME 121/4885ATM 3788/4885PPARG 2984/4885
US-20040186151-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MME 1348/4885ATM 2862/4885PPARG 2024/4885
US-20230398224-A1 TARGETED PLASMA PROTEIN DEGRADATION M6PR, ASGR1, IGF2R MME 131/4885ATM 3997/4885PPARG 3714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback